Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Adlai Nortye Ltd. American Depositary Shares (ANL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: ANL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.76% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.72M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta -0.89 | 52 Weeks Range 0.88 - 2.99 | Updated Date 11/14/2025 |
52 Weeks Range 0.88 - 2.99 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date 2025-12-03 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1220.88% |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -103.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22774409 | Price to Sales(TTM) 29.1 |
Enterprise Value 22774409 | Price to Sales(TTM) 29.1 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA - | Shares Outstanding 31236934 | Shares Floating 66714945 |
Shares Outstanding 31236934 | Shares Floating 66714945 | ||
Percent Insiders 8.59 | Percent Institutions 0.19 |
Upturn AI SWOT
Adlai Nortye Ltd. American Depositary Shares
Company Overview
History and Background
Adlai Nortye Ltd. is a biopharmaceutical company focused on the discovery and development of innovative cancer immunotherapies. It was founded in 2016. The company's primary focus is on developing therapies for challenging and difficult-to-treat cancers.
Core Business Areas
- Oncology Drug Development: Adlai Nortye is dedicated to developing novel immuno-oncology therapies, including small molecule inhibitors and antibody-drug conjugates, targeting unmet medical needs in cancer treatment.
Leadership and Structure
Information on Adlai Nortye Ltd.'s specific leadership team and organizational structure is not readily available in a consolidated public format suitable for this JSON structure. Typically, such a structure would include a CEO, CSO, CFO, and various department heads, with a Board of Directors overseeing governance.
Top Products and Market Share
Key Offerings
- Product Name 1: Adlai Nortye's pipeline includes several novel drug candidates in various stages of clinical development. One prominent candidate is INM001, a novel small molecule inhibitor targeting specific tumor microenvironment pathways. Market share data for specific pipeline drugs is not yet established as they are in development. Competitors would depend on the specific target and therapeutic area of each drug candidate, but broadly include other oncology drug developers such as Bristol Myers Squibb, Merck & Co., and Pfizer, among many others.
Market Dynamics
Industry Overview
The oncology drug market is a dynamic and rapidly growing sector driven by increasing cancer incidence, advancements in scientific understanding of cancer biology, and the pursuit of more effective and targeted therapies. Immunotherapy has emerged as a significant pillar of cancer treatment, with substantial investment and ongoing innovation.
Positioning
Adlai Nortye is positioned as an emerging player in the oncology immunotherapy space, aiming to develop differentiated therapies for difficult-to-treat cancers. Its competitive advantage lies in its innovative approach to targeting specific pathways within the tumor microenvironment and its focus on unmet medical needs.
Total Addressable Market (TAM)
The global oncology market is valued in hundreds of billions of dollars and is projected to continue significant growth. Adlai Nortye's TAM is a subset of this, focusing on specific cancer indications and patient populations where its therapies are intended to be used. The company is positioning itself to capture a share of this market as its pipeline assets progress through development and towards commercialization.
Upturn SWOT Analysis
Strengths
- Focus on innovative immuno-oncology therapies.
- Pipeline of novel drug candidates targeting unmet medical needs.
- Experienced research and development team.
- Strategic partnerships and collaborations.
Weaknesses
- Early-stage development for most pipeline assets.
- Limited commercialization history.
- Reliance on clinical trial success.
- Significant capital requirements for drug development.
Opportunities
- Growing demand for effective cancer immunotherapies.
- Advancements in understanding tumor biology and microenvironment.
- Potential for strategic acquisitions or licensing deals.
- Expansion into new cancer indications.
Threats
- Intense competition in the oncology drug market.
- Stringent regulatory hurdles and lengthy approval processes.
- High costs of clinical trials and drug development.
- Potential for unexpected adverse events in clinical trials.
- Patent expirations and generic competition for established therapies.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck & Co., Inc. (MRK)
- Pfizer Inc. (PFE)
- Roche Holding AG (RHHBY)
- AstraZeneca PLC (AZN)
Competitive Landscape
Adlai Nortye faces a highly competitive landscape dominated by large pharmaceutical companies with established R&D capabilities, extensive clinical trial networks, and significant commercial infrastructure. Its advantages lie in its specialized focus on novel immunotherapies and its agility as a smaller, more focused entity. However, it faces disadvantages in terms of scale, resources, and established market presence compared to its larger rivals.
Growth Trajectory and Initiatives
Historical Growth: Adlai Nortye's historical growth has been characterized by its scientific advancements, progress in its drug development pipeline, and successful fundraising efforts to support its operations.
Future Projections: Future growth projections for Adlai Nortye are contingent on the successful development and regulatory approval of its drug candidates. Analyst estimates would typically focus on potential peak sales of its lead assets and the overall market opportunity they address.
Recent Initiatives: Recent initiatives likely include advancing its lead drug candidates through clinical trials, forging strategic partnerships for development and commercialization, and securing necessary funding through equity offerings or collaborations.
Summary
Adlai Nortye Ltd. is an emerging biopharmaceutical company focused on novel cancer immunotherapies. While it possesses promising pipeline assets and a specialized approach, it operates in a highly competitive and capital-intensive industry. Its success hinges on the progression and approval of its drug candidates, making it a high-risk, high-reward investment. Close monitoring of clinical trial results and strategic partnerships is crucial for evaluating its trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor relations materials (as publicly available).
- Industry analysis reports.
- Financial data aggregators (e.g., Yahoo Finance, Google Finance - for general market information, specific company data availability may vary).
Disclaimers:
This JSON output is generated based on publicly available information and general industry knowledge. It is not a substitute for professional financial advice. The data and analysis presented are for informational purposes only and do not constitute an offer to buy or sell any securities. Investment decisions should be made after consulting with a qualified financial advisor and conducting thorough due diligence. Market share data for early-stage companies is often speculative and may not accurately reflect current commercial presence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | Co- Founder, CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.adlainortye.com |
Full time employees 123 | Website https://www.adlainortye.com | ||
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.